Plavix News and Research

RSS

Better understanding of clotting dynamics in atherosclerosis could lead to more effective drugs

The disease atherosclerosis involves the build up of fatty tissue within arterial walls, creating unstable structures known as plaques. These plaques grow until they burst, rupturing the wall and causing the formation of a blood clot within the artery. These clots also grow until they block blood flow; in the case of the coronary artery, this can cause a heart attack.

8 Nov 2012

Most patients taking common blood-thinning drugs may be receiving wrong dosage levels

Cardiology researchers at the Intermountain Medical Center Heart Institute have found that approximately 75 percent of patients taking two common blood-thinning drugs may be receiving the wrong dosage levels, according to a new study.

8 Nov 2012

Scripps Health receives Qualcomm Foundation grant to support digital medicine research projects

Scripps Health announced today that it has been awarded a $3.75 million grant from the Qualcomm Foundation, to be used for the Scripps Translational Science Institute, which was established by Scripps Health in collaboration with various parties to support the development of breakthrough digital technologies designed to revolutionize the practice of medicine.

4 Oct 2012

Bristol-Myers Squibb, Sanofi restructure long-term alliance

Sanofi and Bristol-Myers Squibb Company today announced they have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets.

4 Oct 2012

Combination of POZEN’s PA32540 and clopidogrel results in greater antiplatelet effects

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced the presentation of Phase 1 data, at the European Society of Cardiologists 2012 Congress, from a study of PA32540, a novel coordinated-delivery tablet of enteric-coated (EC) aspirin (325 mg) and immediate-release (IR) omeprazole (40 mg).

30 Aug 2012

Brand-name drug makers bet coupons will help their products edge out generic competition

If brand-name prescription medicines cost you as little as generic pills, which would you choose? A few drugmakers are betting Americans will stick with the name they know. They've begun offering U.S. patients coupons to reduce copayments on brand-name medicines and compete with new generic versions of the drugs.

22 Aug 2012

First Edition: August 21, 2012

Today's headlines include reports from the campaign trail, where House candidates are turning up the Medicare debate; and from the health care marketkplace, where Aetna acquired Coventry Health, a Medicare and Medicaid insurer.

21 Aug 2012

HCRI announces successful completion of randomization in DAPT Study

The Harvard Clinical Research Institute (HCRI) announced today the successful completion of randomization in the DAPT Study, with the total number of patients randomized exceeding the upper goal set for the Study.

8 Aug 2012

New tool for pharmaceutical industry: VCD from BioTools

Vibrational circular dichroism (VCD), a new tool for determining the absolute configuration of chiral molecules, was a key highlight of the recent 24th International Symposium on Chirality, held June 10-13 in Fort Worth, Texas. VCD pioneer, BioTools (Jupiter, FL) was on hand, not only sponsoring the exhibitor’s luncheon and the poster awards, but also proudly awarding the Best Poster Given by a Young Scientist for the thirteenth year.

12 Jul 2012

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.

9 Jul 2012

HealthWarehouse total net sales increase 82% to $10,363,293 for the year ended Dec. 31, 2011

HealthWarehouse.com, Inc. a leading VIPPS accredited retail mail-order pharmacy, today announced its financial results for the year ended December 31, 2011.

23 Jun 2012

Janssen receives FDA complete response letter for XARELTO sNDA

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).

22 Jun 2012

Studies outline dilemmas on new generic heart drugs, hormone replacement therapy

One heart drug's move to generic status has complicated treatment options for some patients and doctors, the Wall Street Journal reports. Also, another study raises concerns about hormone replacement therapy in women.

30 May 2012

FDA gives patients less-expensive option, approves first generic versions of Plavix

Patients taking the popular blood thinner Plavix now have the option of getting a less-expensive pill, following the approval Thursday of the first generic versions in the U.S. That's because the patent for Plavix, the world's second-best-selling medicine, just expired. Plavix is taken by millions of people every day to prevent heart attacks and strokes, by preventing platelets in the blood from clumping together.

19 May 2012

First Edition: May 18, 2012

Today's headlines include a report that congressional conservatives are fighting amongst themselves over health law strategies.

18 May 2012

Dr. Reddy's launches generic version of PLAVIX

Dr. Reddy's Laboratories announced today that it has launched CLOPIDOGREL TABLETS, USP 75 mg & 300 mg, a bioequivalent generic version of PLAVIX, in the U.S. market on May 18, 2012.

18 May 2012

Mylan receives final FDA approval for Clopidogrel Tablets ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clopidogrel Tablets USP, 75 mg and 300 mg.

18 May 2012

Multiple companies receive FDA approval to sell generic Plavix

The U.S. Food and Drug Administration today approved generic versions of the blood thinning drug Plavix (clopidogrel bisulfate), which helps reduce the risk of heart attack and stroke by making it less likely that platelets in the blood will clump and form clots in the arteries.

18 May 2012

Dangerous, complex migraines linked to high risk for stroke

Nicole Soriano had headaches before but nothing like the one that struck in the middle of one summer night. A coincidence led nine days later to Cedars-Sinai Medical Center, where a rare type of migraine was diagnosed and treated - but any moment during that time could have been disastrous.

16 May 2012

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Janssen Research & Development, LLC announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO, an oral anticoagulant, to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome.

10 May 2012

Plavix News and Research

Better understanding of clotting dynamics in atherosclerosis could lead to more effective drugs

Most patients taking common blood-thinning drugs may be receiving wrong dosage levels

Scripps Health receives Qualcomm Foundation grant to support digital medicine research projects

Bristol-Myers Squibb, Sanofi restructure long-term alliance

Combination of POZEN’s PA32540 and clopidogrel results in greater antiplatelet effects

Brand-name drug makers bet coupons will help their products edge out generic competition

First Edition: August 21, 2012

HCRI announces successful completion of randomization in DAPT Study

New tool for pharmaceutical industry: VCD from BioTools

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

HealthWarehouse total net sales increase 82% to $10,363,293 for the year ended Dec. 31, 2011

Janssen receives FDA complete response letter for XARELTO sNDA

Studies outline dilemmas on new generic heart drugs, hormone replacement therapy

FDA gives patients less-expensive option, approves first generic versions of Plavix

First Edition: May 18, 2012

Dr. Reddy's launches generic version of PLAVIX

Mylan receives final FDA approval for Clopidogrel Tablets ANDA

Multiple companies receive FDA approval to sell generic Plavix

Dangerous, complex migraines linked to high risk for stroke

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News